Kynurenine engenders an immunosuppressive environment by promoting Treg development and decreasing the viability and IFNγ expression of CD8+ T cells, while also directly increasing cancer cell proliferation (Figure 2A) (89–91). The gene discussed is CD8A; the disease is cancer.